Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, multiple news outlets reported Monday, citing a company statement.
The once-daily medication is initially available through private prescription for weight management and type 2 diabetes while undergoing review for state health coverage, the reports said.
The treatment is expected to cost between 100 British pounds ($136.4) and 120 pounds monthly, according to the reports. Foundayo, or orforglipron, was authorized by the UK's Medicines and Healthcare products Regulatory Agency about two weeks ago.
Eli Lilly did not immediately respond to' request for comment.
Shares of the company were down 1.2% in Monday trading.
Price: $1240.13, Change: $-15.27, Percent Change: -1.22%